Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 171Fallopian Tube Neoplasms 85Uterine Cervical Neoplasms 40Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Neoplasms 14Peritoneal Neoplasms 10Colorectal Neoplasms 9Brenner Tumor 9Breast Neoplasms 9Stomach Neoplasms 8Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Diseases 3Melanoma 3Glioblastoma 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Vaccinia 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

nirogacestat 1etoposide phosphate 1Taxes 1Platinum 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Bevacizumab × Gynecologic × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡